approval by FDA for its first anti-PD-L1 cancer immunotherapy namely Tecentriq( atezolizumab), thereby expanding its product portfolio.
Purchase a copy of this report @ http:// www. orbisresearch. com / contact / purchase / 216076. Key benefits
The drivers, restraints, and opportunities in the global cancer biomarkers market are expected to help in understanding the market behavior better. The market estimations are a result of high-end analysis of the key market segments for the period of 2014 – 2022 Projections in the report are made by analyzing the current market trends and future market potential for the forecast period in terms of value. The analysis helps in understanding the strategies adopted by various companies for the growth of the global cancer biomarkers market. Country level analysis has been done to provide micro market sizing of cancer biomarkers in different regions Porter ' s five forces model gives an in-depth analysis of bargaining power of buyers and suppliers, threats of new entrants & substitutes, and competition amongst the key market players.
For more information contact sales @ orbisresearch. com
Some Point’ s from Table of Content:
Chapter 1 Introduction 1.1 Report description 1.2 Key benefits 1.3 Key market segments 1.4 Research methodology 1.4.1 Secondary research 1.4.2 Primary research 1.4.3 Analyst tools and models
Chapter 2 Executive Summary 2.1 CXO perspective
Chapter 3 Market Overview 3.1 Market definition and scope 3.2 Biomarker diagnosis vs. conventional diagnosis 3.3 Key findings 3.3.1 Drivers 3.3.1.1 Rise in incidence and prevalence of various cancer types 3.3.1.2 Growth in importance of biological and targeted drug therapies
3